Progress in genome-inspired treatment decisions for multifocal lung adenocarcinoma

References

• Detterbeck FC, Franklin WA, Nicholson AG, et al. The IASLC lung cancer staging Project: background data and proposed criteria to distinguish separate primary lung cancers from metastatic foci in patients with two lung tumors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(5):651–665. doi: 10.1016/j.jtho.2016.01.025
   PubMed Web of Science ®Google Scholar
• Detterbeck FC, Marom EM, Arenberg DA, et al. The IASLC lung cancer staging Project: background data and proposals for the application of TNM staging rules to lung cancer presenting as multiple nodules with ground glass or lepidic features or a pneumonic type of involvement in the forthcoming eighth edition of the TNM classification. J Thorac Oncol. 2016;11(5):666–680. doi: 10.1016/j.jtho.2015.12.113
   PubMed Web of Science ®Google Scholar
• Detterbeck FC, Nicholson AG, Franklin WA, et al. The IASLC lung cancer staging Project: summary of proposals for revisions of the classification of lung cancers with multiple pulmonary sites of involvement in the forthcoming eighth edition of the TNM classification. J Thorac Oncol. 2016;11(5):639–650. doi: 10.1016/j.jtho.2016.01.024
   PubMed Web of Science ®Google Scholar
• Succony L, Rassl DM, Barker AP, et al. Adenocarcinoma spectrum lesions of the lung: detection, pathology and treatment strategies. Cancer Treat Rev. 2021;99:102237. doi: 10.1016/j.ctrv.2021.102237
   PubMed Web of Science ®Google Scholar
• Lee KH, Goo JM, Park SJ, et al. Correlation between the size of the solid component on thin-section CT and the invasive component on pathology in small lung adenocarcinomas manifesting as ground-glass nodules. J Thorac Oncol. 2014;9(1):74–82. doi: 10.1097/JTO.0000000000000019
   PubMed Web of Science ®Google Scholar
• Cohen JG, Reymond E, Lederlin M, et al. Differentiating pre- and minimally invasive from invasive adenocarcinoma using CT-features in persistent pulmonary part-solid nodules in caucasian patients. Eur J Radiol. 2015;84(4):738–744. doi: 10.1016/j.ejrad.2014.12.031
   PubMed Web of Science ®Google Scholar
• Mirka H, FERDA J, KRAKOROVA G, et al. The use of CT pattern in differentiating non-invasive, minimally invasive and invasive variants of lung adenocarcinoma. Anticancer Res. 2021;41(9):4479–4482. doi: 10.21873/anticanres.15257
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244–285. doi: 10.1097/JTO.0b013e318206a221
   PubMed Web of Science ®Google Scholar
• Nicholson AG, Tsao MS, Beasley MB, et al. The 2021 WHO classification of lung tumors: impact of Advances Since 2015. J Thorac Oncol. 2022;17(3):362–387. doi: 10.1016/j.jtho.2021.11.003
   PubMed Web of Science ®Google Scholar
• Mun M, Kohno T. Efficacy of thoracoscopic resection for multifocal bronchioloalveolar carcinoma showing pure ground-glass opacities of 20 mm or less in diameter. J Thorac Cardiovasc Surg. 2007;134(4):877–882. doi: 10.1016/j.jtcvs.2007.06.010
   PubMed Web of Science ®Google Scholar
• Nakata M, Sawada S, Yamashita M, et al. Surgical treatments for multiple primary adenocarcinoma of the lung. Ann Thorac Surg. 2004;78(4):1194–1199. doi: 10.1016/j.athoracsur.2004.03.102
   PubMed Web of Science ®Google Scholar
• Vazquez M, Carter D, Brambilla E, et al. Solitary and multiple resected adenocarcinomas after CT screening for lung cancer: histopathologic features and their prognostic implications. Lung Cancer. 2009;64(2):148–154. doi: 10.1016/j.lungcan.2008.08.009
   PubMed Web of Science ®Google Scholar
• Kim HY, Shim YM, Lee KS, et al. Persistent pulmonary nodular ground-glass opacity at thin-section CT: histopathologic comparisons. Radiology. 2007;245(1):267–275. doi: 10.1148/radiol.2451061682
   PubMed Web of Science ®Google Scholar
• Kadota K, Nitadori J-I, Sima CS, et al. Tumor spread through air spaces is an important pattern of invasion and impacts the frequency and location of recurrences after limited resection for small stage I lung adenocarcinomas. J Thorac Oncol. 2015;10(5):806–814. doi: 10.1097/JTO.0000000000000486
   PubMed Web of Science ®Google Scholar
• Shih AR, Mino-Kenudson M. Updates on spread through air spaces (STAS) in lung cancer. Histopathology. 2020;77(2):173–180. doi: 10.1111/his.14062
   PubMed Web of Science ®Google Scholar
• Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977;74(12):5463–5467. doi: 10.1073/pnas.74.12.5463
   PubMed Web of Science ®Google Scholar
• Schloss JA, Gibbs RA, Makhijani VB, et al. Cultivating DNA sequencing technology after the Human genome Project. Annu Rev Genomics Hum Genet. 2020;21(1):117–138. doi: 10.1146/annurev-genom-111919-082433
   PubMedGoogle Scholar
• Hu T, Chitnis N, Monos D, et al. Next-generation sequencing technologies: an overview. Hum Immunol. 2021;82(11):801–811. doi: 10.1016/j.humimm.2021.02.012
   PubMed Web of Science ®Google Scholar
• Yohe S, Thyagarajan B. Review of clinical Next-generation sequencing. Arch Pathol Lab Med. 2017;141(11):1544–1557. doi: 10.5858/arpa.2016-0501-RA
   PubMed Web of Science ®Google Scholar
• van Dijk EL, Auger H, Jaszczyszyn Y, et al. Ten Years of next-generation sequencing technology. Trends Genet. 2014;30(9):418–426. doi: 10.1016/j.tig.2014.07.001
   PubMed Web of Science ®Google Scholar
• McCombie WR, McPherson JD, Mardis ER. Next-generation sequencing technologies. Cold Spring Harb Perspect Med. 2019;9(11):9(11. doi: 10.1101/cshperspect.a036798
   Web of Science ®Google Scholar
• International Human Genome Sequencing, C. Finishing the euchromatic sequence of the human genome. Nature. 2004;431(7011):931–945. doi: 10.1038/nature03001
   PubMed Web of Science ®Google Scholar
• Dehghan A. Genome-wide association studies. Methods Mol Biol 2018;1793:37–49.
   PubMedGoogle Scholar
• Visscher PM, Brown M, McCarthy M, et al. Five years of GWAS discovery. Am J Hum Genet. 2012;90(1):7–24. doi: 10.1016/j.ajhg.2011.11.029
   PubMed Web of Science ®Google Scholar
• Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019;18(12):1091–1102. doi: 10.1016/S1474-4422(19)30320-5
   PubMed Web of Science ®Google Scholar
• Franke A, McGovern DPB, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet. 2010;42(12):1118–1125. doi: 10.1038/ng.717
   PubMed Web of Science ®Google Scholar
• Liang B, Ding H, Huang L, et al. GWAS in cancer: progress and challenges. Mol Genet Genomics. 2020;295(3):537–561. doi: 10.1007/s00438-020-01647-z
   PubMed Web of Science ®Google Scholar
• Wang Z, Jensen MA, Zenklusen JC. A practical guide to the cancer genome Atlas (TCGA). Methods Mol Biol, 2016;1418:111–141.
   PubMedGoogle Scholar
• Cheng PF, Dummer R, Levesque MP. Data mining the cancer genome Atlas in the era of precision cancer medicine. Swiss Med Wkly. 2015;145:w14183. doi: 10.4414/smw.2015.14183
   PubMed Web of Science ®Google Scholar
• Genomes Project C, Abecasis GR, Altshuler DM, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68–74. doi: 10.1038/nature15393
   PubMed Web of Science ®Google Scholar
• Murray J. The “all of us research program. N Engl J Med. 2019;381(19):1884.
   PubMedGoogle Scholar
• Fairley S, Lowy-Gallego E, Perry E, et al. The International genome sample resource (IGSR) collection of open human genomic variation resources. Nucleic Acids Res. 2020;48(D1):D941–D947. doi: 10.1093/nar/gkz836
   PubMed Web of Science ®Google Scholar
• Wetterstrand K The Cost Of Sequencing a Human Genome. [cited 2023 May 14]. Available from: https://www.genome.gov/about-genomics/fact-sheets/Sequencing-Human-Genome-cost
   Google Scholar
• Sboner A, Mu X, Greenbaum D, et al. The real cost of sequencing: higher than you think! Genome Biol. 2011;12(8):125. doi: 10.1186/gb-2011-12-8-125
   PubMed Web of Science ®Google Scholar
• Mardis ER. The journal,000 genome, the journal00,000 analysis? Genome Med. 2010;2(11):84. doi: 10.1186/gm205
   PubMed Web of Science ®Google Scholar
• Davey DD, Austin RM, Birdsong G, et al. The impact of the clinical laboratory improvement amendments of 1988 on cytopathology practice: a 25th anniversary review. J Am Soc Cytopathol. 2014;3(4):188–198. doi: 10.1016/j.jasc.2014.04.004
   PubMedGoogle Scholar
• Rehm HL, Bale SJ, Bayrak-Toydemir P, et al. ACMG clinical laboratory standards for next-generation sequencing. Genet Med. 2013;15(9):733–747. doi: 10.1038/gim.2013.92
   PubMed Web of Science ®Google Scholar
• Rehder C, Bean LJH, Bick D, et al. Next-generation sequencing for constitutional variants in the clinical laboratory, 2021 revision: a technical standard of the American College of medical genetics and genomics (ACMG). Genet Med. 2021;23(8):1399–1415. doi: 10.1038/s41436-021-01139-4
   PubMed Web of Science ®Google Scholar
• Jennings LJ, Arcila ME, Corless C, et al. Guidelines for validation of Next-generation sequencing–based oncology panels. J Mol Diagn. 2017;19(3):341–365. doi: 10.1016/j.jmoldx.2017.01.011
   PubMed Web of Science ®Google Scholar
• The Next Generation Sequencing Quality Initiative. [cited 2023 May 14]. Available from: https://www.cdc.gov/labquality/ngs-quality-initiative.html
   Google Scholar
• Cho M, Ahn S, Hong M, et al. Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center’s experiences. Oncotarget. 2017;8(26):42478–42486. doi: 10.18632/oncotarget.17199
   PubMedGoogle Scholar
• Gaffney EF, Riegman PH, Grizzle WE, et al. Factors that drive the increasing use of FFPE tissue in basic and translational cancer research. Biotechnic Histochemist. 2018;93(5):373–386. doi: 10.1080/10520295.2018.1446101
   PubMed Web of Science ®Google Scholar
• Jacobsen SB, Tfelt-Hansen J, Smerup MH, et al. Comparison of whole transcriptome sequencing of fresh, frozen, and formalin-fixed, paraffin-embedded cardiac tissue. PLoS One. 2023;18(3):e0283159. doi: 10.1371/journal.pone.0283159
   PubMed Web of Science ®Google Scholar
• Hedegaard J, Thorsen K, Lund MK, et al. Next-generation sequencing of RNA and DNA isolated from paired fresh-frozen and formalin-fixed paraffin-embedded samples of human cancer and normal tissue. PLoS One. 2014;9(5):e98187. doi: 10.1371/journal.pone.0098187
   PubMed Web of Science ®Google Scholar
• McDonough SJ, Bhagwate A, Sun Z, et al. Use of FFPE-derived DNA in next generation sequencing: DNA extraction methods. PLoS One. 2019;14(4):e0211400. doi: 10.1371/journal.pone.0211400
   PubMed Web of Science ®Google Scholar
• Zhao JJ, Chan HP, Soon YY, et al. A systematic review and meta-analysis of the adequacy of endobronchial ultrasound transbronchial needle aspiration for next-generation sequencing in patients with non-small cell lung cancer. Lung Cancer. 2022;166:17–26. doi: 10.1016/j.lungcan.2022.01.018
   PubMed Web of Science ®Google Scholar
• Diep R, MacDonald M, Cooper R, et al. Biopsy method and needle size on success of Next-generation sequencing in NSCLC: a brief report. JTO Clin Res Rep. 2023;4(4):100497. doi: 10.1016/j.jtocrr.2023.100497
   PubMedGoogle Scholar
• Martin-Deleon R, Teixido C, Lucena CM, et al. EBUS-TBNA Cytological samples for Comprehensive molecular testing in non–small cell lung cancer. Cancers (Basel). 2021;13(9):2084. doi: 10.3390/cancers13092084
   PubMed Web of Science ®Google Scholar
• Zhang C, Kim RY, McGrath CM, et al. The performance of an extended Next generation sequencing panel using endobronchial ultrasound-guided fine needle aspiration samples in non-Squamous non-small cell lung cancer: a pragmatic study. Clin Lung Cancer. 2023;24(2):e105–e112. doi: 10.1016/j.cllc.2022.11.010
   PubMed Web of Science ®Google Scholar
• Lyons TG. Targeted therapies for triple-negative breast cancer. Curr Treat Options Oncol. 2019;20(11):82. doi: 10.1007/s11864-019-0682-x
   PubMed Web of Science ®Google Scholar
• Patel TH, Cecchini M. Targeted therapies in advanced gastric cancer. Curr Treat Options Oncol. 2020;21(9):70. doi: 10.1007/s11864-020-00774-4
   PubMed Web of Science ®Google Scholar
• Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325(7):669–685. doi: 10.1001/jama.2021.0106
   PubMed Web of Science ®Google Scholar
• Cagle PT, Chirieac LR. Advances in treatment of lung cancer with targeted therapy. Arch Pathol Lab Med. 2012;136(5):504–509. doi: 10.5858/arpa.2011-0618-RA
   PubMed Web of Science ®Google Scholar
• Qian Y, Gong Y, Fan Z, et al. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. J Hematol Oncol. 2020;13(1):130. doi: 10.1186/s13045-020-00958-3
   PubMed Web of Science ®Google Scholar
• Benson AB, Venook AP, Al-Hawary MM, et al. Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(10):1139–1167. doi: 10.6004/jnccn.2022.0051
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Moran MS, Abraham J, et al. Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(6):691–722. doi: 10.6004/jnccn.2022.0030
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Wood DE, Aisner DL, et al. NCCN guidelines® insights: non–small cell lung cancer, version 2.2023. J Natl Compr Canc Netw. 2023;21(4):340–350. doi: 10.6004/jnccn.2023.0020
   PubMedGoogle Scholar
• Stobbe MD, Thun GA, Diéguez-Docampo A, et al. Recurrent somatic mutations reveal new insights into consequences of mutagenic processes in cancer. PLoS Comput Biol. 2019;15(11):e1007496. doi: 10.1371/journal.pcbi.1007496
   PubMed Web of Science ®Google Scholar
• Landau J, Tsaban L, Yaacov A, et al. Shared cancer dataset analysis identifies and predicts the quantitative effects of pan-cancer somatic driver variants. Cancer Res. 2023;83(1):74–88. doi: 10.1158/0008-5472.CAN-22-1038
   PubMed Web of Science ®Google Scholar
• Consortium ITP-CAOWG, Abascal F, Abeshouse A. Pan-cancer analysis of whole genomes. Nature. 2020;578(7793):82–93. doi: 10.1038/s41586-020-1969-6
   PubMed Web of Science ®Google Scholar
• Meirson T, Bomze D, Schueler-Furman O, et al. Systemic structural analysis of alterations reveals a common structural basis of driver mutations in cancer. NAR Cancer. 2023;5(1):zcac040. doi: 10.1093/narcan/zcac040
   PubMedGoogle Scholar
• Pilarski R. How have multigene panels changed the clinical practice of genetic counseling and testing. J Natl Compr Canc Netw. 2021;19(1):103–108. doi: 10.6004/jnccn.2020.7674
   PubMed Web of Science ®Google Scholar
• Sheikine Y, Kuo FC, Lindeman NI. Clinical and technical aspects of genomic diagnostics for precision oncology. J Clin Oncol. 2017;35(9):929–933. doi: 10.1200/JCO.2016.70.7539
   PubMed Web of Science ®Google Scholar
• Kopetz S, Mills Shaw KR, Lee JJ, et al. Use of a targeted exome Next-generation sequencing panel offers therapeutic opportunity and clinical benefit in a subset of patients with advanced cancers. JCO Precis Oncol. 2019;(3):1–14. doi: 10.1200/PO.18.00213
   PubMedGoogle Scholar
• Vail E, Song J, Xu J, et al. Comparison of large, medium, and small solid tumor gene panels for detection of clinically actionable mutations in cancer. Targ Oncol. 2020;15(4):523–530. doi: 10.1007/s11523-020-00743-9
   PubMed Web of Science ®Google Scholar
• Miller EM, Patterson NE, Zechmeister JM, et al. Development and validation of a targeted next generation DNA sequencing panel outperforming whole exome sequencing for the identification of clinically relevant genetic variants. Oncotarget. 2017;8(60):102033–102045. doi: 10.18632/oncotarget.22116
   PubMedGoogle Scholar
• Santos E, Martin-Zanca D, Reddy EP, et al. Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science. 1984;223(4637):661–664. doi: 10.1126/science.6695174
   PubMed Web of Science ®Google Scholar
• Rusch V, Baselga J, Cordon-Cardo C, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 1993;53(10 Suppl):2379–2385.
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-Cell lung cancer to Gefitinib. N Engl J Med. 2004;350(21):2129–2139. doi: 10.1056/NEJMoa040938
   PubMed Web of Science ®Google Scholar
• Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–1500. doi: 10.1126/science.1099314
   PubMed Web of Science ®Google Scholar
• Shih JY, Gow CH, Yang PC. EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer. N Engl J Med. 2005;353(2):207–208. doi: 10.1056/NEJM200507143530217
   PubMed Web of Science ®Google Scholar
• Reita D, Pabst L, Pencreach E, et al. Molecular mechanism of EGFR-TKI resistance in EGFR-Mutated non-small cell lung cancer: application to biological diagnostic and monitoring. Cancers (Basel). 2021;13(19):4926. doi: 10.3390/cancers13194926
   PubMed Web of Science ®Google Scholar
• Kosaka T, Yatabe Y, Endoh H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non–small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res. 2006;12(19):5764–5769. doi: 10.1158/1078-0432.CCR-06-0714
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. N Engl J Med. 2017;376(7):629–640. doi: 10.1056/NEJMoa1612674
   PubMed Web of Science ®Google Scholar
• Herbst RS, Gandara DR, Hirsch FR, et al. Lung master protocol (lung-MAP)—A biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400. Clin Cancer Res. 2015;21(7):1514–1524. doi: 10.1158/1078-0432.CCR-13-3473
   PubMed Web of Science ®Google Scholar
• Steuer CE, Papadimitrakopoulou V, Herbst RS, et al. Innovative clinical trials: the LUNG-MAP study. Clin Pharmacol Ther. 2015;97(5):488–491. doi: 10.1002/cpt.88
   PubMed Web of Science ®Google Scholar
• Girard N, Ostrovnaya I, Lau C, et al. Genomic and mutational profiling to assess clonal relationships between multiple non–small cell lung cancers. Clin Cancer Res. 2009;15(16):5184–5190. doi: 10.1158/1078-0432.CCR-09-0594
   PubMed Web of Science ®Google Scholar
• Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg. 1975;70(4):606–612. doi: 10.1016/S0022-5223(19)40289-4
   PubMed Web of Science ®Google Scholar
• Goodwin D, Rathi V, Conron M, et al. Genomic and clinical significance of multiple primary lung cancers as determined by Next-generation sequencing. J Thorac Oncol. 2021;16(7):1166–1175. doi: 10.1016/j.jtho.2021.03.018
   PubMed Web of Science ®Google Scholar
• Antakli T, Schaefer RF, Rutherford JE, et al. Second primary lung cancer. Ann Thorac Surg. 1995;59(4):863–866. discussion 867. doi: 10.1016/0003-4975(95)00067-U
   PubMed Web of Science ®Google Scholar
• Shen KR, Meyers BF, Larner JM, et al. Special treatment issues in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(3):290S–305S. doi: 10.1378/chest.07-1382
   PubMed Web of Science ®Google Scholar
• Kozower BD, Larner JM, Detterbeck FC, et al. Special treatment issues in non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5):e369–e399. doi: 10.1378/chest.12-2362
   Web of Science ®Google Scholar
• Donfrancesco E, Yvorel V, Casteillo F, et al. Histopathological and molecular study for synchronous lung adenocarcinoma staging. Virchows Arch. 2020;476(6):835–842. doi: 10.1007/s00428-019-02736-0
   PubMed Web of Science ®Google Scholar
• Girard N, Deshpande C, Azzoli CG, et al. Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines. Chest. 2010;137(1):46–52. doi: 10.1378/chest.09-0325
   PubMed Web of Science ®Google Scholar
• Sozzi G, Miozzo M, Pastorino U, et al. Genetic evidence for an independent origin of multiple preneoplastic and neoplastic lung lesions. Cancer Res. 1995;55(1):135–140.
   PubMed Web of Science ®Google Scholar
• van Rens MT, Eijken EJE, Elbers JRJ, et al. p53 mutation analysis for definite diagnosis of multiple primary lung carcinoma. Cancer. 2002;94(1):188–196. doi: 10.1002/cncr.10001
   PubMed Web of Science ®Google Scholar
• Hiroshima K, Toyozaki T, Kohno H, et al. Synchronous and metachronous lung carcinomas: molecular evidence for multicentricity. Pathol Int. 1998;48(11):869–876. doi: 10.1111/j.1440-1827.1998.tb03853.x
   PubMed Web of Science ®Google Scholar
• Matsuzoe D, Hideshima T, Ohshima K, et al. Discrimination of double primary lung cancer from intrapulmonary metastasis by p53 gene mutation. Br J Cancer. 1999;79(9–10):1549–1552. doi: 10.1038/sj.bjc.6690247
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Yatabe Y, Koshikawa T, et al. Mutations of the P53 tumor suppressor gene as clonal marker for multiple primary lung cancers. J Thorac Cardiovasc Surg. 1997;114(3):354–360. doi: 10.1016/S0022-5223(97)70180-6
   PubMed Web of Science ®Google Scholar
• Cai X, Sheng J, Tang C, et al. Frequent mutations in EGFR, KRAS and TP53 genes in human lung cancer tumors detected by ion torrent DNA sequencing. PLoS One. 2014;9(4):e95228. doi: 10.1371/journal.pone.0095228
   PubMed Web of Science ®Google Scholar
• Navin NE, Hicks J. Tracing the tumor lineage. Mol Oncol. 2010;4(3):267–283. doi: 10.1016/j.molonc.2010.04.010
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–566. doi: 10.1038/nature05945
   PubMed Web of Science ®Google Scholar
• Murphy SJ, Aubry M-C, Harris FR, et al. Identification of independent primary tumors and intrapulmonary metastases using DNA rearrangements in non–small-Cell lung cancer. J Clin Oncol. 2014;32(36):4050–4058. doi: 10.1200/JCO.2014.56.7644
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang J, Li L, et al. Genomic heterogeneity of multiple synchronous lung cancer. Nat Commun. 2016;7(1):13200. doi: 10.1038/ncomms13200
   PubMed Web of Science ®Google Scholar
• Murphy SJ, Harris FR, Kosari F, et al. Using genomics to differentiate multiple primaries from metastatic lung cancer. J Thorac Oncol. 2019;14(9):1567–1582. doi: 10.1016/j.jtho.2019.05.008
   PubMed Web of Science ®Google Scholar
• Patel SB, Kadi W, Walts AE, et al. Next-generation sequencing: a novel approach to distinguish multifocal primary lung adenocarcinomas from intrapulmonary metastases. J Mol Diagn. 2017;19(6):870–880. doi: 10.1016/j.jmoldx.2017.07.006
   PubMed Web of Science ®Google Scholar
• Saab J, Zia H, Mathew S, et al. Utility of genomic analysis in differentiating synchronous and metachronous lung adenocarcinomas from primary adenocarcinomas with intrapulmonary metastasis. Transl Oncol. 2017;10(3):442–449. doi: 10.1016/j.tranon.2017.02.009
   PubMed Web of Science ®Google Scholar
• Roepman P, ten Heuvel A, Scheidel KC, et al. Added value of 50-gene panel sequencing to distinguish multiple primary lung cancers from pulmonary metastases: a systematic investigation. J Mol Diagn. 2018;20(4):436–445. doi: 10.1016/j.jmoldx.2018.02.007
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Shien K, Tomida S, et al. Comparative mutational evaluation of multiple lung cancers by multiplex oncogene mutation analysis. Cancer Sci. 2018;109(11):3634–3642. doi: 10.1111/cas.13797
   PubMed Web of Science ®Google Scholar
• Mansuet-Lupo A, Barritault M, Alifano M, et al. Proposal for a combined histomolecular algorithm to distinguish multiple primary adenocarcinomas from intrapulmonary metastasis in patients with multiple lung tumors. J Thorac Oncol. 2019;14(5):844–856. doi: 10.1016/j.jtho.2019.01.017
   PubMed Web of Science ®Google Scholar
• Duan J, Ge M, Peng J, et al. Application of large-scale targeted sequencing to distinguish multiple lung primary tumors from intrapulmonary metastases. Sci Rep. 2020;10(1):18840. doi: 10.1038/s41598-020-75935-4
   PubMed Web of Science ®Google Scholar
• Leventakos K, Peikert T, Midthun DE, et al. Management of multifocal lung cancer: results of a survey. J Thorac Oncol. 2017;12(9):1398–1402. doi: 10.1016/j.jtho.2017.05.013
   PubMed Web of Science ®Google Scholar
• Amin MB, American joint committee on cancer., and American cancer society., In: AJCC cancer staging manual. Eight edition/editor-in-chief, Mahul B. Amin MD, FCAP; editors Stephen B. Edge M, FACS and 16 others; Donna M, Gress RHIT, CTR - Technical editor; Laura R. eds Meyer, CAPM - Managing editor Vol. xvii. Chicago IL: American Joint Committee on Cancer: Springer; 2017. p. 1024.
   Google Scholar
• Chang JC, Alex D, Bott M, et al. Comprehensive Next-generation sequencing unambiguously distinguishes separate primary lung carcinomas from intrapulmonary metastases: comparison with standard histopathologic approach. Clin Cancer Res. 2019;25(23):7113–7125. doi: 10.1158/1078-0432.CCR-19-1700
   PubMed Web of Science ®Google Scholar
• Arcila ME, Yang S-R, Momeni A, et al. Ultrarapid EGFR mutation screening followed by Comprehensive Next-generation sequencing: a feasible, informative approach for lung carcinoma cytology specimens with a high success rate. JTO Clin Res Rep. 2020;1(3):1(3. doi: 10.1016/j.jtocrr.2020.100077
   PubMedGoogle Scholar
• Li R, Li X, Xue R, et al. Early metastasis detected in patients with multifocal pulmonary ground-glass opacities (GGOs). Thorax. 2018;73(3):290–292. doi: 10.1136/thoraxjnl-2017-210169
   PubMed Web of Science ®Google Scholar
• Detterbeck FC. Multifocal adenocarcinoma: perspectives, assumptions and elephants. J Thorac Dis. 2018;10(3):1193–1197. doi: 10.21037/jtd.2018.01.173
   PubMed Web of Science ®Google Scholar
• Garfield DH, Cadranel JL, Wislez M, et al. The bronchioloalveolar carcinoma and peripheral adenocarcinoma spectrum of diseases. J Thorac Oncol. 2006;1(4):344–359. doi: 10.1016/S1556-0864(15)31593-8
   PubMed Web of Science ®Google Scholar
• West HJ. Managing multifocal bronchioloalveolar carcinoma/lepidic predominant adenocarcinoma: changing rules for an evolving clinical entity. Clin Adv Hematol Oncol. 2014;12(9):593–600.
   PubMedGoogle Scholar
• Kim BG, Um SW. A narrative review of the clinical approach to subsolid pulmonary nodules. Ann Transl Med. 2023;11(5):217. doi: 10.21037/atm-22-5246
   PubMedGoogle Scholar
• Battafarano RJ, Meyers BF, Guthrie TJ, et al. Surgical resection of multifocal non-small cell lung cancer is associated with prolonged survival. Ann Thorac Surg. 2002;74(4):988–994. discussion 993-4. doi: 10.1016/S0003-4975(02)03878-X
   PubMed Web of Science ®Google Scholar
• Roberts PF, Straznicka M, Lara PN, et al. Resection of multifocal non–small cell lung cancer when the bronchioloalveolar subtype is involved. J Thorac Cardiovasc Surg. 2003;126(5):1597–1601. doi: 10.1016/S0022-5223(03)01280-7
   PubMed Web of Science ®Google Scholar
• Hattori A, Matsunaga T, Takamochi K, et al. Surgical management of multifocal ground-glass opacities of the lung: correlation of clinicopathologic and radiologic findings. Thorac Cardiovasc Surg. 2017;65(2):142–149. doi: 10.1055/s-0036-1572437
   PubMed Web of Science ®Google Scholar
• Gao RW, Berry MF, Kunder CA, et al. Survival and risk factors for progression after resection of the dominant tumor in multifocal, lepidic-type pulmonary adenocarcinoma. J Thorac Cardiovasc Surg. 2017;154(6):2092–2099 e2. doi: 10.1016/j.jtcvs.2017.07.034
   PubMed Web of Science ®Google Scholar
• Ji Y, Bai G, Qiu B, et al. The surgical management of early-stage lung adenocarcinoma: is wedge resection effective? J Thorac Dis. 2021;13(4):2137–2147. doi: 10.21037/jtd-20-3005
   PubMed Web of Science ®Google Scholar
• Waller DA. Surgical management of lung cancer with multiple lesions: implication of the new recommendations of the 8(th) edition of the TNM classification for lung cancer. J Thorac Dis. 2018;10(Suppl S22):S2686–S2691. doi: 10.21037/jtd.2018.04.159
   PubMedGoogle Scholar
• Zuin A, Andriolo LG, Marulli G, et al. Is lobectomy really more effective than sublobar resection in the surgical treatment of second primary lung cancer? Eur J Cardiothorac Surg. 2013;44(2):e120–5. discussion e125. doi: 10.1093/ejcts/ezt219
   PubMed Web of Science ®Google Scholar
• Chen TF, Xie C-Y, Rao B-Y, et al. Surgical treatment to multiple primary lung cancer patients: a systematic review and meta-analysis. BMC Surg. 2019;19(1):185. doi: 10.1186/s12893-019-0643-0
   PubMed Web of Science ®Google Scholar
• Yang H, Sun Y, Yao F, et al. Surgical therapy for bilateral multiple primary lung cancer. Ann Thorac Surg. 2016;101(3):1145–1152. doi: 10.1016/j.athoracsur.2015.09.028
   PubMed Web of Science ®Google Scholar
• Shimada Y, Saji H, Otani K, et al. Survival of a surgical series of lung cancer patients with synchronous multiple ground-glass opacities, and the management of their residual lesions. Lung Cancer. 2015;88(2):174–180. doi: 10.1016/j.lungcan.2015.02.016
   PubMed Web of Science ®Google Scholar
• Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung cancer study group. Ann Thorac Surg. 1995;60(3):615–622. discussion 622-3. doi: 10.1016/0003-4975(95)00537-U
   PubMed Web of Science ®Google Scholar
• Altorki N, Wang X, Kozono D, et al. Lobar or sublobar resection for peripheral stage IA non–small-Cell lung cancer. N Engl J Med. 2023;388(6):489–498. doi: 10.1056/NEJMoa2212083
   PubMed Web of Science ®Google Scholar
• Aokage K, Suzuki K, Saji H, et al. Segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less including ground-glass opacity (JCOG1211): a multicentre, single-arm, confirmatory, phase 3 trial. Lancet Respir Med. 2023;11(6):540–549. doi: 10.1016/S2213-2600(23)00041-3
   PubMed Web of Science ®Google Scholar
• Owen D, Olivier KR, Mayo CS, et al. Outcomes of stereotactic body radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules. Radiat Oncol. 2015;10(1):43. doi: 10.1186/s13014-015-0340-9
   PubMedGoogle Scholar
• Nikitas J, DeWees T, Rehman S, et al. Stereotactic body radiotherapy for early-stage multiple primary lung cancers. Clin Lung Cancer. 2019;20(2):107–116. doi: 10.1016/j.cllc.2018.10.010
   PubMed Web of Science ®Google Scholar
• Sinha B, McGarry RC. Stereotactic body radiotherapy for bilateral primary lung cancers: the Indiana University experience. Int J Radiat Oncol Biol Phys. 2006;66(4):1120–1124. doi: 10.1016/j.ijrobp.2006.06.042
   PubMed Web of Science ®Google Scholar
• Creach KM, Bradley JD, Mahasittiwat P, et al. Stereotactic body radiation therapy in the treatment of multiple primary lung cancers. Radiother Oncol. 2012;104(1):19–22. doi: 10.1016/j.radonc.2011.12.005
   PubMed Web of Science ®Google Scholar
• Matthiesen C, Thompson JS, De La Fuente Herman T, et al. Use of stereotactic body radiation therapy for medically inoperable multiple primary lung cancer. J Med Imaging Radiat Oncol. 2012;56(5):561–566. doi: 10.1111/j.1754-9485.2012.02393.x
   PubMed Web of Science ®Google Scholar
• Chang JY, Liu Y-H, Zhu Z, et al. Stereotactic ablative radiotherapy: a potentially curable approach to early stage multiple primary lung cancer. Cancer. 2013;119(18):3402–3410. doi: 10.1002/cncr.28217
   PubMed Web of Science ®Google Scholar
• Griffioen GH, Lagerwaard FJ, Haasbeek CJA, et al. Treatment of multiple primary lung cancers using stereotactic radiotherapy, either with or without surgery. Radiother Oncol. 2013;107(3):403–408. doi: 10.1016/j.radonc.2013.04.026
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Yamazaki T, Sato S, et al. Surgery or stereotactic body radiotherapy for metachronous primary lung cancer? A propensity score matching analysis. Gen Thorac Cardiovasc Surg. 2020;68(11):1305–1311. doi: 10.1007/s11748-020-01394-3
   PubMed Web of Science ®Google Scholar
• Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA. 2019;322(8):764–774. doi: 10.1001/jama.2019.11058
   PubMed Web of Science ®Google Scholar
• Wu C, Zhao C, Yang Y, et al. High discrepancy of driver mutations in patients with NSCLC and synchronous multiple lung ground-glass nodules. J Thorac Oncol. 2015;10(5):778–783. doi: 10.1097/JTO.0000000000000487
   PubMed Web of Science ®Google Scholar
• Liu M, He W-X, Song N, et al. Discrepancy of epidermal growth factor receptor mutation in lung adenocarcinoma presenting as multiple ground-glass opacities. Eur J Cardiothorac Surg. 2016;50(5):909–913. doi: 10.1093/ejcts/ezw113
   PubMedGoogle Scholar
• Ye C, Wang J, Li W, et al. Novel strategy for synchronous multiple primary lung cancer displaying unique molecular profiles. Ann Thorac Surg. 2016;101(2):e45–7. doi: 10.1016/j.athoracsur.2015.06.042
   PubMed Web of Science ®Google Scholar
• Guardant360 CDx – P200010. 2020 [cited 2023 May 11]. Available from: https://www.fda.gov/medical-devices/recently-approved-devices/guardant360-cdx-p200010
   Google Scholar
• Foundation One Liquid CDx – P190032. 2020 [cited 2023 May 11]. Available from: https://www.fda.gov/medical-devices/recently-approved-devices/foundationone-liquid-cdx-p190032
   Google Scholar
• Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883–892. doi: 10.1056/NEJMoa1113205
   PubMed Web of Science ®Google Scholar
• Yadav SS, Stockert JA, Hackert V, et al. Intratumor heterogeneity in prostate cancer. Urol Oncol. 2018;36(8):349–360. doi: 10.1016/j.urolonc.2018.05.008
   PubMed Web of Science ®Google Scholar
• Burrell RA, Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol. 2014;8(6):1095–1111. doi: 10.1016/j.molonc.2014.06.005
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339(6127):1546–1558. doi: 10.1126/science.1235122
   PubMed Web of Science ®Google Scholar
• Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467(7319):1114–1117. doi: 10.1038/nature09515
   PubMed Web of Science ®Google Scholar
• McGranahan N, Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell. 2015;27(1):15–26. doi: 10.1016/j.ccell.2014.12.001
   PubMed Web of Science ®Google Scholar
• Ma P, Fu Y, Cai M-C, et al. Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer. Nat Commun. 2017;8(1):823. doi: 10.1038/s41467-017-00963-0
   PubMed Web of Science ®Google Scholar
• Izumi M, Oyanagi J, Sawa K, et al. Mutational landscape of multiple primary lung cancers and its correlation with non-intrinsic risk factors. Sci Rep. 2021;11(1):5680. doi: 10.1038/s41598-021-83609-y
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang G, Zheng H, et al. Distinct gene mutation profiles among multiple and single primary lung adenocarcinoma. Front Oncol. 2022;12:1014997. doi: 10.3389/fonc.2022.1014997
   PubMed Web of Science ®Google Scholar
• De Mattos-Arruda L, Weigelt B, Cortes J, et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann Oncol. 2014;25(9):1729–1735. doi: 10.1093/annonc/mdu239
   PubMed Web of Science ®Google Scholar
• Chabon JJ, Simmons AD, Lovejoy AF, et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun. 2016;7(1):11815. doi: 10.1038/ncomms11815
   PubMed Web of Science ®Google Scholar
• Roosan MR, Mambetsariev I, Pharaon R, et al. Usefulness of circulating tumor DNA in identifying somatic mutations and tracking tumor evolution in patients with non-small cell lung cancer. Chest. 2021;160(3):1095–1107. doi: 10.1016/j.chest.2021.04.016
   PubMed Web of Science ®Google Scholar
• Russo M, Siravegna G, Blaszkowsky LS, et al. Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Cancer Discov. 2016;6(2):147–153. doi: 10.1158/2159-8290.CD-15-1283
   PubMed Web of Science ®Google Scholar
• Strickler JH, Loree JM, Ahronian LG, et al. Genomic landscape of cell-free DNA in patients with colorectal cancer. Cancer Discov. 2018;8(2):164–173. doi: 10.1158/2159-8290.CD-17-1009
   PubMed Web of Science ®Google Scholar
• Diaz Jr LA Jr., Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486(7404):537–540. doi: 10.1038/nature11219
   PubMed Web of Science ®Google Scholar
• Kuo YB, Chen J-S, Fan C-W, et al. Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer. Clin Chim Acta. 2014;433:284–289. doi: 10.1016/j.cca.2014.03.024
   PubMed Web of Science ®Google Scholar
• Parikh AR, Leshchiner I, Elagina L, et al. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med. 2019;25(9):1415–1421. doi: 10.1038/s41591-019-0561-9
   PubMed Web of Science ®Google Scholar
• Remon J, Lacroix L, Jovelet C, et al. Real-world utility of an amplicon-based Next-generation sequencing liquid biopsy for broad molecular profiling in patients with advanced non–small-Cell lung cancer. JCO Precis Oncol. 2019;3(3):1–14. doi: 10.1200/PO.18.00211
   Google Scholar
• Leighl NB, Page RD, Raymond VM, et al. Clinical utility of Comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non–small cell lung cancer. Clin Cancer Res. 2019;25(15):4691–4700. doi: 10.1158/1078-0432.CCR-19-0624
   PubMed Web of Science ®Google Scholar
• Nigro MC, Marchese PV, Deiana C, et al. Clinical utility and application of liquid biopsy genotyping in lung cancer: a comprehensive review. Lung Cancer. 2023;14:11–25. doi: 10.2147/LCTT.S388047
   PubMed Web of Science ®Google Scholar
• Kowalik A, Kowalewska M, Gozdz S. Current approaches for avoiding the limitations of circulating tumor cells detection methods-implications for diagnosis and treatment of patients with solid tumors. Transl Res. 2017;185:58–84 e15. doi: 10.1016/j.trsl.2017.04.002
   PubMed Web of Science ®Google Scholar
• Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4(136):136ra68. doi: 10.1126/scitranslmed.3003726
   PubMed Web of Science ®Google Scholar
• Misale S, Di Nicolantonio F, Sartore-Bianchi A, et al. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov. 2014;4(11):1269–1280. doi: 10.1158/2159-8290.CD-14-0462
   PubMed Web of Science ®Google Scholar
• Lanman RB, Mortimer SA, Zill OA, et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS One. 2015;10(10):e0140712. doi: 10.1371/journal.pone.0140712
   PubMed Web of Science ®Google Scholar
• Rolfo C, Mack P, Scagliotti GV, et al. Liquid biopsy for advanced NSCLC: a consensus statement from the International association for the study of lung cancer. J Thorac Oncol. 2021;16(10):1647–1662. doi: 10.1016/j.jtho.2021.06.017
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Frigola J, Vendrell E, et al. Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. Cancer Res. 2006;66(17):8462–9468. doi: 10.1158/0008-5472.CAN-06-0293
   PubMed Web of Science ®Google Scholar
• Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet. 2007;16(1):R50–9. doi: 10.1093/hmg/ddm018
   PubMedGoogle Scholar
• Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349(21):2042–2054. doi: 10.1056/NEJMra023075
   PubMed Web of Science ®Google Scholar
• Fullgrabe J, Gosal WS, Creed P, et al. Simultaneous sequencing of genetic and epigenetic bases in DNA. Nat Biotechnol. 2023;41(10):1457–1464. doi: 10.1038/s41587-022-01652-0
   PubMed Web of Science ®Google Scholar
• Zhang J, Yang C, Wu C, et al. DNA methyltransferases in cancer: biology, paradox, Aberrations, and targeted therapy. Cancers (Basel). 2020;12(8):12(8. doi: 10.3390/cancers12082123
   Web of Science ®Google Scholar
• Cheng Y, He C, Wang M, et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Sig Transduct Target Ther. 2019;4(1):62. doi: 10.1038/s41392-019-0095-0
   PubMedGoogle Scholar
• Yu X, Li M, Guo C, et al. Therapeutic targeting of cancer: epigenetic homeostasis. Front Oncol. 2021;11:747022. doi: 10.3389/fonc.2021.747022
   PubMed Web of Science ®Google Scholar
• Jin N, George TL, Otterson GA, et al. Advances in epigenetic therapeutics with focus on solid tumors. Clin Epigenetics. 2021;13(1):83. doi: 10.1186/s13148-021-01069-7
   PubMed Web of Science ®Google Scholar